People · Operator
Named in public records as an officer, director or promoter · active 2020–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NEUROONE MEDICAL TECHNOLOGIES Corp | — | Biotechnology | Series A | $21.2M | $1.4M | 2020 |
Edward A. Andrle at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Edward A. Andrle on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David A. Rosa | 1 | 5 |
| JEFFREY S. MATHIESEN | 1 | 4 |
| Paul A Buckman | 1 | 3 |
| Ronald A. McClurg | 1 | 2 |
| Thomas A. Bachinski | 1 | 2 |
| Mark A. Christianson | 1 | 2 |
| Suraj A. Kalia | 1 | 2 |
| Paul S. Buckman | 1 | 2 |
| Mark S. Christianson | 1 | 1 |
| Steve A. Mertens | 1 | 1 |
| Christopher A. Volker | 1 | 1 |
| Ronald S. McClurg | 1 | 1 |
| Suraj S. Kalia | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.